Good & fair points, thanks Tom.
And the only reason I joined here on ihub was to try and figure out if this Anavex compound was still showing cognitive stabilization/improvement after the 12 month promising charts were released back in Dec 2016.
Absent updates from the Company, I'm STILL trying to use deductions & logic & shared knowledge since the Company has not put much food on our plate in 9 months.
Perhaps they are speaking (through actions)??? That's what each of us must decide.
Perhaps it is logical to assume that mgmt and SAB are sufficiently pleased with the extension results SINCE they'd assumably wish to AVOID being accused of giving investors false hope (by taking the 5 recent actions)?
Is that all we really need to know? That (while it was only n=25) it's REASONABLE to assume for now that they have positive continuing results in hand?
I personally don't believe in placebo effect for Alzheimer's patients and I don't believe that "dose dependent cognitive improvement" is just a coincidence even in a pool of only 25 patients. Not logical to me.
Regardless, either the Company gives us more data assurances SOON to keep retail invested, or we likely will see even more selling pressure.
GLTAL. All must DYODD. Just my opinions and observations per usual.
News 
Market Data 
Discover 
